Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
2.050
-0.060 (-2.84%)
At close: May 12, 2025, 4:00 PM
2.050
0.00 (0.00%)
After-hours: May 12, 2025, 6:49 PM EDT
Heron Therapeutics Revenue
Heron Therapeutics had revenue of $38.90M in the quarter ending March 31, 2025, with 12.21% growth. This brings the company's revenue in the last twelve months to $148.52M, up 12.43% year-over-year. In the year 2024, Heron Therapeutics had annual revenue of $144.29M with 13.57% growth.
Revenue (ttm)
$148.52M
Revenue Growth
+12.43%
P/S Ratio
2.11
Revenue / Employee
$1,217,361
Employees
122
Market Cap
312.76M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 144.29M | 17.24M | 13.57% |
Dec 31, 2023 | 127.04M | 19.37M | 17.99% |
Dec 31, 2022 | 107.67M | 21.33M | 24.70% |
Dec 31, 2021 | 86.35M | -2.29M | -2.59% |
Dec 31, 2020 | 88.64M | -57.33M | -39.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
HRTX News
- 5 days ago - Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025 - Seeking Alpha
- 6 days ago - Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates - PRNewsWire
- 6 days ago - Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations - PRNewsWire
- 14 days ago - Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer - PRNewsWire
- 20 days ago - Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025 - PRNewsWire
- 2 months ago - Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates - PRNewsWire